Clinical Trial Update: Pharmacokinetics of IV Formulation [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study of an intravenous formulation from F2G Biotech GmbH for invasive aspergillosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Aspergillosis

Snippet

Sponsor: F2G Biotech GmbH | Conditions: Invasive Aspergillosis | Phase 1 | Status: WITHDRAWN